Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

被引：0

作者：

Lin, C-C. ^{[1
]}

Schneider, R. ^{[2
]}

Gutierrez, M. ^{[3
]}

Shen, L. ^{[4
]}

Chung, K. ^{[5
]}

Doroshow, D. B. ^{[6
]}

Gao, B. ^{[7
,8
]}

Millward, M. ^{[9
]}

Hsieh, C-Y. ^{[10
]}

Xu, C. ^{[10
]}

Cai, S. X. ^{[10
]}

Tian, Y. E. ^{[10
]}

Liu, L. ^{[10
]}

Shen, C. ^{[10
]}

Tan, Y. ^{[10
]}

He, Y. ^{[10
]}

Zhang, C. ^{[10
]}

Li, L. ^{[11
]}

Ma, M. ^{[10
]}

Xu, L. ^{[10
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[2] Mary Crowley Canc Res, Dept Med Oncol, Dallas, TX USA

[3] Hackensack Univ, Dept Med Oncol, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[4] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China

[5] Prisma Hlth Syst Upstate, Clin Res, Inst Translat Oncol Res, Greenville, SC USA

[6] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA

[7] Blacktown Hosp, Haematol & Canc Care Ctr, Blacktown, NSW, Australia

[8] Univ Sydney, Blacktown, NSW, Australia

[9] Linear Clin Res, Oncol, Perth, WA, Australia

[10] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China

[11] IQVIA RDS Shanghai Co Ltd, Beijing Branch, Med, Beijing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.699

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

632P

引用

页码：S503 / S504

页数：2

共 50 条

[21] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
Hollebecque, Antoine
Soria, Jean-Charles
Bahleda, Ratislav
Lopez-Busto, Natividad
Jacquet-Bescond, Anne
Burbridge, Mike F.
Valerie, Cattan
Pauly, Jeanne
Herranz, Maria
Azaro, Analia
Depil, Stephane
Rodon, Jordi
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[22] First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
Sessa, Cristiana
Shapiro, Geoffrey I.
Bhalla, Kapil N.
Britten, Carolyn
Jacks, Karen S.
Mita, Monica
Papadimitrakopoulou, Vali
Pluard, Tim
Samuel, Thomas A.
Akimov, Mikhail
Quadt, Cornelia
Fernandez-Ibarra, Cristina
Lu, Hong
Bailey, Stuart
Chica, Sandra
Banerji, Udai
CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3671 - 3680
[23] A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A)
Dillon, Magnus T.
Espinasse, Aude
Ellis, Sally
Mohammed, Kabir
Grove, Lorna G.
McLellan, Lyndall
Smith, Simon A.
Ross, Graham
Adeleke, Sola
Woo, Kin
Josephides, Eleni
Spicer, James F.
Forster, Martin D.
Harrington, Kevin J.
CANCER RESEARCH, 2017, 77
[24] A first-in-human (FIH) phase I study of SAR12544, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results
Angevin, Eric
Spitaleri, Gianluca
Hollebecque, Antoine
De Pas, Tommaso
Soria, Jean-Charles
Harnols, Marzia
Mazuir, Florent
Assadourlan, Sylvie
De Marinis, Filippo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[25] First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part
Doi, Toshihiko
Matsubara, Nobuaki
Naito, Yoichi
Kuboki, Yasutoshi
Harano, Kenichi
Ono, Makiko
Urasaki, Tetsuya
Ohmoto, Akihiro
Kawanai, Tsubasa
Hisai, Takashi
Ikezawa, Hiroki
Shiba, Sari
Ito, Ken
Semba, Taro
Asano, Osamu
Takahashi, Shunji
CANCER, 2023, 129 (15) : 2348 - 2359
[26] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
Piha-Paul, Sarina Anne
Wan, Qunfang
Xiong, Wendy
Peng, Peng
Yang, Xiaoju
Wu, Henry
Ngo, Brenda
Wu, Frank
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Lieu, C.
Lenz, H. J.
Kim, K. P.
Sung, M. J.
Kim, U-I.
Meng, X.
Benson, A. B., III
ANNALS OF ONCOLOGY, 2024, 35 : S504 - S504
[28] Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
Fedyanin, Mikhail
Tryakin, Alexey
Lisyanskaya, Alla Sergeevna
Solovyeva, Ekaterina
Fadeeva, Natalia
Gladkov, Oleg
Moiseyenko, Vladimir
Cheporov, Sergey, V
Shpigotskaya, Polina
Purmal, Andrei
Miller, Langdon L.
Leonov, Andrey
Zakurdaeva, Kristina
Gurova, Katerina
Gudkov, Andrei
Tjulandin, Sergei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results
Gutierrez, Martin
Spreafico, Anna
Wang, Ding
Golan, Talia
Renouf, Daniel
Voskoboynik, Mark
Chatterjee, Manash Shankar
Kapadia, Kishan J.
Liu, Qi
Kovvali, Gopala
Suttner, Leah
Pang, Ling
Chen, Mei
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
Harvey, R. Donald
Falchook, Gerald Steven
Naqash, Abdul Rafeh
Kim, Joseph W.
Dowlati, Afshin
Le Bruchec, Yvan
Coudert, Isabelle
Ervin-Haynes, Annette L.
Sommerhalder, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →